NeuroAct Communication offers expert guidance to scientific communication.

  • Define a publication strategy: identify objectives, target audience, journals
  • Aid to effective presentation of pharmacological data
  • Experienced scientific writing and editing: research reports, posters, symposia

For more information Contact.
 

 

Analgesia & SNRI

Key message: some chronic pain pathologies, such as fibromyalgia syndrome (FMS) are associated with chronic stress. Drugs that inhibit serotonin and noradrenaline reuptake exhibit anti-stress and analgesic activity.

  • Chronic stress elicits allodynia, hyperalgesia and elevated plasma BDNF release in a rat repeated restraint stress regimen.
  • The SNRIs, milnacipran (Savella ® ) and duloxetine (Cymbalta ®), as well as another analgesic, pregabalin (Lyrica ® ), attenuate repeated restraint stress-induced allodynia and BDNF release.
  • The late, inflammatory phase of formalin-induced pain can provide a rodent screen for potential anti-FMS / chronic pain compounds.
  • The SNRIs milnacipran and duloxetine oppose stress-induced ultrasonic vocalisation in rat.
# Article Title
1 Milnacipran is active in models of irritable bowel syndrome and abdominal visceral pain in rodents.
2 Effects of milnacipran, duloxetine and indomethacin, in polyarthritic rats using the Randall-Selitto model.
3 Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain.
4 Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: Relevance to human stress-associated painful pathologies.
5 Chronic restraint stress-induced mechanical/cold allodynia and enhanced inflammatory pain in rat: Effects of milnacipran, duloxetine and pregabalin. (POSTER)
6 Repeated restraint stress increases BDNF plasma levels in rat: effects of milnacipran, pregabalin and duloxetine. (POSTER)
7 Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats.
8 Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-HT1A agonist F13640: relationship with 5-HT1A receptor occupancy and kinetic parameters. PDF
9 S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. PDF
Display #